847943-54-8

Basic information

• Product Name: TERT-BUTYL 6-CHLORO-5-HYDROXYNICOTINATE
• Synonyms: TERT-BUTYL 6-CHLORO-5-HYDROXYNICOTINATE;tert-butyl 6-chloro-5-hydroxypyridine-3-carboxylate
• CAS NO: 847943-54-8
• Molecular Formula: C10H12ClNO3
• Molecular Weight: 229.66018
• Mol File: 847943-54-8.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: TERT-BUTYL 6-CHLORO-5-HYDROXYNICOTINATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 6-CHLORO-5-HYDROXYNICOTINATE(847943-54-8)
• EPA Substance Registry System: TERT-BUTYL 6-CHLORO-5-HYDROXYNICOTINATE(847943-54-8)

Safety Data

• Hazardous Substances Data: 847943-54-8(Hazardous Substances Data)

Usage

General Description

TERT-BUTYL 6-CHLORO-5-HYDROXYNICOTINATE is a chemical compound with the molecular formula C14H16ClNO3. It is a derivative of nicotinic acid and belongs to the class of organic compounds known as pyridinecarboxylic acids and derivatives. TERT-BUTYL 6-CHLORO-5-HYDROXYNICOTINATE is commonly used in the pharmaceutical industry for its potential therapeutic applications. It possesses both hydroxy and chloro functional groups, and the tert-butyl group provides stability and enhances its solubility in organic solvents. The presence of the chloro and hydroxy groups also makes it a valuable intermediate for the synthesis of various pharmaceuticals and agrochemicals. Overall, TERT-BUTYL 6-CHLORO-5-HYDROXYNICOTINATE is an important chemical compound with potential applications in the fields of medicine and agrochemicals.

Upstream product

• 847943-53-7 5-hydroxy-nicotinic acid tert-butyl ester 
• 30766-22-4 methyl 5-hydroxy-3-pyridinecarboxylate 

Relevant articles and documents

Discovery, structure - Activity relationship, and pharmacological evaluation of (5-substituted-pyrrolidinyl-2-carbonyl)-2-cyanopyrrolidines as potent dipeptidyl peptidase IV inhibitors

A series of (5-substituted pyrrolidinyl-2-carbonyl)-2-cyanopyrrolidine (C5-Pro-Pro) analogues was discovered as dipeptidyl peptidase IV (DPPIV) inhibitors as a potential treatment of diabetes and obesity. X-ray crystallography data show that these inhibitors bind to the catalytic site of DPPIV with the cyano group forming a covalent bond with the serine residue of DPPIV. The C5-substituents make various interactions with the enzyme and affect potency, chemical stability, selectivity, and PK properties of the inhibitors. Optimized analogues are extremely potent with subnanomolar Ki's, are chemically stable, show very little potency decrease in the presence of plasma, and exhibit more than 1,000-fold selectivity against related peptidases. The best compounds also possess good PK and are efficacious in lowering blood glucose in an oral glucose tolerance test in ZDF rats.

Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)

The present invention relates to compounds of formula (I), which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, syndrome X, hyperinsulinemia, β-cell failure, obesity, satiety disorders, atherosclerosis, and various immunomodulatory diseases.